Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — a 44-amino-acid peptide that is structurally identical to the first 44 amino acids of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification protects the peptide from rapid enzymatic degradation, extending its functional half-life while preserving its natural mechanism of action at the pituitary gland.
Tesamorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, which bypasses the hypothalamic-pituitary axis entirely, tesamorelin preserves the body's natural negative feedback mechanisms. This means growth hormone levels increase within physiological bounds, reducing the risk of supraphysiological GH and IGF-1 concentrations.
Tesamorelin is the only GHRH analogue with full FDA approval (Egrifta, 2010) for a specific indication — reduction of excess abdominal fat in HIV-associated lipodystrophy. Beyond this approved use, clinical studies have demonstrated its effects on visceral fat reduction, triglyceride improvement, cognitive function in mild cognitive impairment, and liver fat reduction in non-alcoholic fatty liver disease, generating significant interest for broader metabolic optimization.
The 3mg/mL compounded injectable delivers tesamorelin subcutaneously for reliable systemic absorption. The subcutaneous route ensures consistent bioavailability and allows for precise dosing under medical supervision, supporting growth hormone optimization as part of a comprehensive health management plan.
Clinician-supervised, delivered to your door.
